Villasboas JC - Search Results

1

Expression of KLRG1 and CD127 defines distinct CD8⁺ subsets that differentially impact patient outcome in follicular lymphoma.

Wu H, Tang X, Kim HJ, Jalali S, Pritchett JC, Villasboas JC, Novak AJ, Yang ZZ, Ansell SM. Wu H, et al. Among authors: villasboas jc. J Immunother Cancer. 2021 Jul;9(7):e002662. doi: 10.1136/jitc-2021-002662. J Immunother Cancer. 2021. PMID: 34226281 Free PMC article.

2

The era of immuno-oncology: are we there yet?

Villasboas JC, Ansell SM. Villasboas JC, et al. Oncology (Williston Park). 2015 Mar;29(3):204-5. Oncology (Williston Park). 2015. PMID: 25772457 Free article. No abstract available.

3

Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.

Villasboas JC, Ansell SM. Villasboas JC, et al. Expert Rev Anticancer Ther. 2016;16(1):5-12. doi: 10.1586/14737140.2016.1121812. Epub 2015 Dec 7. Expert Rev Anticancer Ther. 2016. PMID: 26577822 Review.

4

Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.

Villasboas JC, Ansell S. Villasboas JC, et al. Cancer J. 2016 Jan-Feb;22(1):17-22. doi: 10.1097/PPO.0000000000000164. Cancer J. 2016. PMID: 26841012 Review.

5

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective.

Villasboas JC, Ansell SM, Witzig TE. Villasboas JC, et al. Oncotarget. 2016 Mar 15;7(11):13260-13264. doi: 10.18632/oncotarget.7177. Oncotarget. 2016. PMID: 26848626 Free PMC article.

6

Recent advances in the management of Hodgkin lymphoma.

Villasboas JC, Ansell SM. Villasboas JC, et al. F1000Res. 2016 Apr 27;5:F1000 Faculty Rev-768. doi: 10.12688/f1000research.8301.1. eCollection 2016. F1000Res. 2016. PMID: 27158471 Free PMC article. Review.

7

Glancing at the complex biology of T-cells through the microenvironment of Hodgkin lymphoma.

Villasboas JC, Ansell S. Villasboas JC, et al. Leuk Lymphoma. 2017 May;58(5):1019-1021. doi: 10.1080/10428194.2016.1248966. Epub 2016 Oct 31. Leuk Lymphoma. 2017. PMID: 27794629 No abstract available.

8

Expression of LAG-3 defines exhaustion of intratumoral PD-1⁺ T cells and correlates with poor outcome in follicular lymphoma.

Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska T, Jalali S, Wilson M, Novak AJ, Ansell SM. Yang ZZ, et al. Among authors: villasboas jc. Oncotarget. 2017 May 29;8(37):61425-61439. doi: 10.18632/oncotarget.18251. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 28977875 Free PMC article.

9

Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia.

Jalali S, Price-Troska T, Paludo J, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Ansell SM. Jalali S, et al. Blood Adv. 2018 Aug 14;2(15):1985-1997. doi: 10.1182/bloodadvances.2018021113. Blood Adv. 2018. PMID: 30104397 Free PMC article.

10

Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.

Jalali S, Price-Troska T, Bothun C, Villasboas J, Kim HJ, Yang ZZ, Novak AJ, Dong H, Ansell SM. Jalali S, et al. Blood Cancer J. 2019 Feb 19;9(3):22. doi: 10.1038/s41408-019-0185-9. Blood Cancer J. 2019. PMID: 30783096 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters